EPTIFIBATIDE INJECTION
As listed in the register: EPTIFIBATIDE INJECTION
0.75 mg · solution
- Prescription only
- Blood, clotting and anaemia
- Active substance
- Eptifibatide
- Used in
- Blood, clotting and anaemia
- Made by
- Juno Pharma Canada Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Eptifibatide). It describes the substance, not this exact product.
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
When administered intravenously, eptifibatide inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner.
In healthy subjects, renal clearance accounts for approximately 50% of total body clearance, with the majority of the drug excreted in the urine as eptifibatide, deaminated eptifibatide, and other, more polar metabolites.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-02-09
Safety of the active substance
From the US prescribing label for the same active substance (Eptifibatide). It describes the substance, not this exact product.
- Bleeding diathesis or bleeding within the previous 30 days.
- ( 4 ) Severe uncontrolled hypertension.
- ( 4 ) Major surgery within the preceding 6 weeks.
- ( 4 ) Stroke within 30 days or any history of hemorrhagic stroke.
The most commonly reported adverse reactions.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
Details
| Made by | Juno Pharma Canada Inc. |
|---|---|
| Active substance | Eptifibatide |
| Used in | Blood, clotting and anaemia |
| Strength | 0.75 mg |
| Form | solution |
| Classification | B01AC16 · Blood, clotting and anaemia |
| Route | intravenous |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02540819 |
| DPD drug code | 102949 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
4 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution4 products
0.75 mg2
0.75 mg · 2 companies
- Juno Pharma Canada Inc. · this page
- Strides Pharma Canada Inc
2 mg2
2 mg · 2 companies
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.